Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) - Global Forecasts to 2022

August 2018 | 83 pages | ID: BE3C3C029A8EN
MarketsandMarkets

Abstracts

“Global breast cancer liquid biopsy market projected to grow at a CAGR of 23.1%”

The global breast cancer liquid biopsy market is estimated to grow at a CAGR of 23.1% from 2017 to 2022, from USD 145.4 million in 2017 to reach USD 411.1 million by 2022. Increasing prevalence of breast cancer, increasing preference for noninvasive procedures, and availability of funding for liquid biopsy R&D are some of the key factors driving the growth of the market. Unclear regulatory and reimbursement scenario is one of the major challenges faced by the market.

“Cell-free DNA to register the highest CAGR during the forecast period”

Based on circulating biomarkers, the market is categorized into circulating tumor cells (CTCs), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. The cfDNA segment is the fastest-growing segment in the circulating biomarkers market during the forecast period. This is due to the growing interest in cfDNA research from biofluids such as the blood of cancer patients as a means of disease diagnosis and therapeutic monitoring.

“Reference laboratories to register the largest share during the forecast period”

Based on end user, the market is categorized into reference laboratories, hospitals and physician laboratories, and other end users. The reference laboratories segment is the largest end-user segment of the global breast cancer liquid biopsy market. Reference laboratories are well-equipped large laboratories with facilities for genomic testing of samples, thus receiving major share of samples from hospitals and private practitioners.

“Asia Pacific to witness the highest growth during the forecast period (2017–2022)”

North America is expected to account for the largest share of the global breast cancer liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of breast cancer, and improving healthcare infrastructure are driving the growth of breast cancer liquid biopsy market in this region.

Break of primary participants was as mentioned below:

• By Company Type – Tier 1– 15%, Tier 2– 45%, and Tier 3–40%
• By Designation – C-level– 27%, Director Level–33%, Others–40%
• By Region – North America–25%, Europe–45%, Asia-Pacific–15%, RoW–15%

Some of the major market players in the breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories (US), Myriad Genetics (US), Menarini Silicon Biosystems (Italy), Illumina (US), Cynvenio Biosystems, Inc. (US) Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Fluxion Biosciences, Inc. (US), Biodesix, Inc. (US), Guardant Health, Inc. (US), and Isogen Life Science B.V. (Netherlands).

Research Coverage:

The report analyzes the breast cancer liquid biopsy market and aims at estimating market size and future growth potential of this market based on various segments such as by circulating biomarker, end user, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a greater share. Firms purchasing the report could use one or any combination of the below-mentioned five strategies.

This report provides insights on the following pointers:

• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global liquid biopsy market. The report analyzes the global liquid biopsy market by product, medical specialty, application, end user, and region
• Innovation: Detailed insights on upcoming trends and product launches in the global breast cancer liquid biopsy market
• Market Development: Comprehensive information on the lucrative emerging markets by product, circulating biomarkers, end user, and region
• Market Diversification: Exhaustive information about growing geographies, recent developments, and investments in the global breast cancer liquid biopsy market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, products, and capabilities of liquid biopsy products of leading players in the global market

Contents

1 LIQUID BIOPSY: MARKET AT A GLANCE

1.1 INTRODUCTION
1.2 ISSUES ADDRESSED BY LIQUID BIOPSY & BIOMARKERS DETECTED
1.3 MILESTONES IN LIQUID BIOPSY

2 LIQUID BIOPSY: CIRCULATING BIOMARKERS

2.1 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA (CTDNA)
2.2 CTDNA APPROACHES: APPLICATIONS AND LIMITATIONS
2.3 METHODS FOR CTC ISOLATION

3 LIQUID BIOPSY: MARKET OVERVIEW

3.1 INTRODUCTION
  3.1.1 DRIVERS
    3.1.2.1 HIGH BURDEN OF CANCER
    3.1.2.2 INCREASING PREFERENCE FOR NONINVASIVE PROCEDURES
    3.1.2.3 INITIATIVES UNDERTAKEN BY GOVERNMENTS AND GLOBAL HEALTH ORGANIZATIONS
    3.1.2.4 TECHNOLOGICAL ADVANCEMENTS
    3.1.2.5 RISING EMPHASIS ON PERSONALIZED MEDICINE
    3.1.2.6 AVAILABILITY OF FUNDING FOR LIQUID BIOPSY R&D
  3.1.2 RESTRAINTS
    3.1.2.1 LOW SENSITIVITY AND SPECIFICITY
  3.1.3 OPPORTUNITIES
    3.1.3.1 GROWING INTEREST IN LIQUID BIOPSY
  3.1.4 CHALLENGES
    3.1.4.1 UNCLEAR REGULATORY AND REIMBURSEMENT SCENARIO

4 MAJOR INVESTMENTS & INITIATIVES

4.1 GOVERNMENT FUNDING & INITIATIVES
4.2 INDUSTRY INVESTMENTS AND INITIATIVES

5 BREAST CANCER LIQUID BIOPSY MARKET

5.1 BREAST CANCER LIQUID BIOPSY MARKET: GLOBAL SCENARIO
5.2 POTENTIAL OF LIQUID BIOPSY AND CTC IN BREAST CANCER DIAGNOSIS

6 LIQUID BIOPSY MARKET: COMPETITIVE LANDSCAPE

6.1 INTRODUCTION
6.2 KEY STRATEGIES
  6.2.1 ACQUISITIONS AND MERGERS
  6.2.2 PRODUCT LAUNCHES
  6.2.3 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
6.3 LIQUID BIOPSY MARKET: COMPETITIVE TECHNOLOGY PORTFOLIO

7 APPENDIX

7.1 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
7.2 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
7.3 AVAILABLE CUSTOMIZATIONS
7.4 RELATED REPORTS
7.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

Table 1 CTDNA APPROACHES: APPLICATIONS AND LIMITATIONS
Table 2 METHODS FOR CTC ISOLATION-1
Table 3 METHODS FOR CTC ISOLATION -2
Table 4 CONFERENCES & AWARENESS PROGRAMS ON LIQUID BIOPSY
Table 5 UPCOMING CONFERENCES & AWARENESS PROGRAMS ON LIQUID BIOPSY
Table 6 GOVERNMENT FUNDING & INITIATIVES – NORTH AMERICA
Table 7 GOVERNMENT FUNDING & INITIATIVES – EUROPE
Table 8 GOVERNMENT FUNDING & INITIATIVES – ASIA PACIFIC
Table 9 GOVERNMENT FUNDING & INITIATIVES – REST OF THE WORLD
Table 10 MAJOR INVESTMENTS IN THE LIQUID BIOPSY MARKET (2010–2017) -1,2,3,4,5,6
Table 11 BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2015-2022 (USD MILLION)
Table 12 BREAST CANCER LIQUID BIOPSY MARKET, BY REGION, 2015-2022 (USD MILLION)
Table 13 BREAST CANCER LIQUID BIOPSY MARKET, BY END USER, 2015-2022 (USD MILLION)
Table 14 BREAST CANCER CTDNA MARKET, BY REGION, 2015-2022 (USD MILLION)
Table 15 MAJOR PLAYERS AND COMPETITIVE TECHNOLOGY PORTFOLIO – 1,2,3,4,5,6,7

List Of Figures

LIST OF FIGURES

Figure 1 ISSUES ADDRESSED BY LIQUID BIOPSY
Figure 2 LIQUID BIOPSY: DETECTION OF CANCER BIOMARKERS
Figure 3 MILESTONES IN LIQUID BIOPSY
Figure 4 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 5 GLOBAL CANCER MORTALITY STATISTICS (2012)
Figure 6 BIOMARKERS USED IN CURRENT LIQUID BIOPSY TESTS
Figure 7 PUBMED PUBLICATIONS ON LIQUID BIOPSY
Figure 8 INVESTMENTS IN LIQUID BIOPSY: 2016 & 2017 (USED MILLION)
Figure 9 NGS FUND-RAISING IN 2017 (USD MILLION)
Figure 10 BREAST CANCER LIQUID BIOPSY: MARKET OVERVIEW
Figure 11 LIQUID BIOPSY MARKET BY CIRCULATING BIOMARKERS (CAGR 2017 – 2022)